Zacks Investment Research Downgrades MDXHealth (MXDHF) to Sell

MDXHealth (OTCMKTS:MXDHF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

According to Zacks, “MDxHealth SA is a healthcare company which provides actionable molecular diagnostic information for diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation and other molecular technologies and assist physicians with the diagnosis of cancer. MDxHealth SA is headquartered in Herstal, Belgium. “

MDXHealth (MXDHF) opened at $4.30 on Wednesday. MDXHealth has a 52 week low of $3.80 and a 52 week high of $6.15.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Downgrades MDXHealth (MXDHF) to Sell” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2018/01/17/zacks-investment-research-downgrades-mdxhealth-mxdhf-to-sell.html.

About MDXHealth

MDxHealth SA, a molecular diagnostics company, develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients in Belgium and internationally. The company’s tests are based on genetic, epigenetic (methylation) and other molecular technologies, and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy.

Get a free copy of the Zacks research report on MDXHealth (MXDHF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MDXHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDXHealth and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply